Literature DB >> 7749132

Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomy.

Y Nomura1, H Tashiro, A Osaki.   

Abstract

Longer survival data are necessary to elucidate the prognostic factors for survival in advanced breast cancer patients. Univariate and multivariate analyses were performed in 159 patients treated with adreno-oophorectomy alone as the first-line treatment for advanced or recurrent breast cancer, between 1972 and 1983. Nine clinical factors included age, menopausal status, estrogen (ER)- and progesterone receptors (PgR) in recurrent tumors, disease-free interval (DFI), number of metastatic organs, performance status, and adjuvant therapy performed. Response was evaluated according to the UICC criteria. A 31% (50/159) response with 16 CR, 34 PR, 48 NC, and 61 PD was obtained. The logistic regression model of the factors showed that ER was the single affecting factor for the response. According to the Cox proportional hazard model, ER and the dominant site of metastasis were indicated to be significant for survival. According to the landmark method, the response significantly correlated to survival. Using the backward elimination procedure of the Cox proportional hazard model in the patient group defined by the landmark time of 3 months after therapy, the survival of the patients with advanced breast cancer was shown to be primarily influenced by the tumor response which was solely affected by ER status, and the dominant site, particularly the presence of liver metastasis, independently modified the survival length. These results may be useful in future studies of total estrogen blockade trials for breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749132     DOI: 10.1007/BF00666070

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Goserelin depot in the treatment of premenopausal advanced breast cancer.

Authors:  R W Blamey; W Jonat; M Kaufmann; A R Bianco; M Namer
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer.

Authors:  Y Nomura; S Miura; H Koyama; K Enomoto; F Kasumi; H Yamamoto; M Kimura; T Tominaga; H Iino; T Morimoto
Journal:  Cancer       Date:  1992-01-01       Impact factor: 6.860

3.  Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer.

Authors:  D P Byar; M E Sears; W L McGuire
Journal:  Eur J Cancer       Date:  1979-03       Impact factor: 9.162

4.  Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials.

Authors:  J R Anderson; K C Cain; R D Gelber; R S Gelman
Journal:  Cancer Treat Rep       Date:  1985-10

Review 5.  Survival after first recurrence of breast cancer. The Miami experience.

Authors:  C L Vogel; S Azevedo; S Hilsenbeck; D R East; J Ayub
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

6.  Reporting results from chemotherapy trials. Does response make a difference in patient survival?

Authors:  R K Oye; M F Shapiro
Journal:  JAMA       Date:  1984-11-16       Impact factor: 56.272

7.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

8.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

Authors:  G M Clark; G W Sledge; C K Osborne; W L McGuire
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

9.  Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients.

Authors:  A Alanko; E Heinonen; T Scheinin; E M Tolppanen; R Vihko
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

10.  Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients.

Authors:  L L Shek; W Godolphin; J J Spinelli
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.